Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Jacobus J.M. van der Hoeven"'
Autor:
Karijn P.M. Suijkerbuijk, Ellen Kapiteijn, John B.A.G. Haanen, Michel W.J.M. Wouters, Michiel C.T. van Zeijl, Gerard Vreugdenhil, Astrid A.M. van der Veldt, Albert J. ten Tije, Rozemarijn S. van Rijn, Djura Piersma, Geke A. Hospers, Jacobus J.M. van der Hoeven, Marye J. Boers-Sonderen, Jan Willem B. de Groot, Alfonsus J.M. van den Eertwegh, Franchette W.P.J. van den Berkmortel, Maureen J.B. Aarts, Christian U. Blank, Anne M. May, Rik J. Verheijden
Suppl. tab. S1 | Multivariable Cox regression of baseline factors associated with overall survival in all first-line checkpoint inhibitor treated patients Suppl. tab. S2 | Multivariable Cox regression of baseline factors associated with overall survi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::742a384f917f9cb609af63491e5128a5
https://doi.org/10.1158/1078-0432.22477943.v1
https://doi.org/10.1158/1078-0432.22477943.v1
Autor:
Karijn P.M. Suijkerbuijk, Ellen Kapiteijn, John B.A.G. Haanen, Michel W.J.M. Wouters, Michiel C.T. van Zeijl, Gerard Vreugdenhil, Astrid A.M. van der Veldt, Albert J. ten Tije, Rozemarijn S. van Rijn, Djura Piersma, Geke A. Hospers, Jacobus J.M. van der Hoeven, Marye J. Boers-Sonderen, Jan Willem B. de Groot, Alfonsus J.M. van den Eertwegh, Franchette W.P.J. van den Berkmortel, Maureen J.B. Aarts, Christian U. Blank, Anne M. May, Rik J. Verheijden
Purpose:Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause severe immune-related toxicity necessitating immunosuppressive treatment. Whether immunosuppression for toxicity impacts survival is largely unknown.Experimental Design:Usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b6e5a41e7d9c2db771ce20ae378f9d
https://doi.org/10.1158/1078-0432.c.6529805
https://doi.org/10.1158/1078-0432.c.6529805
Autor:
John B. A. G. Haanen, Maureen J.B. Aarts, Michel W.J.M. Wouters, Albert J. ten Tije, Astrid A M van der Veldt, Karijn P M Suijkerbuijk, Rozemarijn S. van Rijn, Alfons J.M. van den Eertwegh, Liesbeth C. de Wreede, Ellen Kapiteijn, Geke A. P. Hospers, Franchette W P J van den Berkmortel, Jacobus J.M. van der Hoeven, Gerard Vreugdenhil, Michiel C T van Zeijl, Jan-Willem B de Groot, Djura Piersma
Publikováno v:
International Journal of Cancer, 150(2), 317-326. Wiley-Liss Inc.
International Journal of Cancer, 150(2), 317-326. Wiley
International Journal of Cancer, 150(2), 317-326. WILEY
International Journal of Cancer, 150, 2, pp. 317-326
International Journal of Cancer, 150, 317-326
van Zeijl, M C T, van den Eertwegh, A J M, Wouters, M W J M, de Wreede, L C, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, van der Veldt, A A M, Vreugdenhil, G, van der Hoeven, J J M & Haanen, J B A G 2022, ' Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice ', International Journal of Cancer, vol. 150, no. 2, pp. 317-326 . https://doi.org/10.1002/ijc.33800
International Journal of Cancer, 150(2), 317-326. Wiley
International Journal of Cancer, 150(2), 317-326. WILEY
International Journal of Cancer, 150, 2, pp. 317-326
International Journal of Cancer, 150, 317-326
van Zeijl, M C T, van den Eertwegh, A J M, Wouters, M W J M, de Wreede, L C, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, van der Veldt, A A M, Vreugdenhil, G, van der Hoeven, J J M & Haanen, J B A G 2022, ' Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice ', International Journal of Cancer, vol. 150, no. 2, pp. 317-326 . https://doi.org/10.1002/ijc.33800
Contains fulltext : 287666.pdf (Publisher’s version ) (Open Access) There is no consensus on the optimal treatment duration of anti-PD-1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti-PD-1 discontinuation,
Autor:
Christian U. Blank, Astrid A M van der Veldt, Alfonsus J M van den Eertwegh, Ellen Kapiteijn, Anne M. May, Djura Piersma, Rik J Verheijden, Geke A. P. Hospers, Michel W.J.M. Wouters, Maureen J.B. Aarts, Marye Boers-Sonderen, Karijn P M Suijkerbuijk, Albert J. ten Tije, Franchette W P J van den Berkmortel, Jacobus J.M. van der Hoeven, Rozemarijn S. van Rijn, Jan Willem B. de Groot, Michiel C T van Zeijl, John B. A. G. Haanen, Gerard Vreugdenhil
Publikováno v:
ESMO OPEN, 5(6):000945. BMJ Publishing Group
Esmo Open, 5, 6
Esmo Open, 5
ESMO Open, 5(6):e000945. BMJ Publishing Group
ESMO Open, Vol 5, Iss 6 (2020)
ESMO Open, 5(6):000945. BMJ Publishing Group
ESMO Open, 5(6):000945. BMJ PUBLISHING GROUP
Verheijden, R J, May, A M, Blank, C U, van der Veldt, A A M, Boers-Sonderen, M J, Aarts, M J B, van den Berkmortel, F W P J, van den Eertwegh, A J M, de Groot, J W B, van der Hoeven, J J M, Hospers, G A P, Piersma, D, van Rijn, R S, ten Tije, A J, Vreugdenhil, G, van Zeijl, M C T, Wouters, M W J M, Haanen, J B A G, Kapiteijn, E & Suijkerbuijk, K P M 2020, ' Lower risk of severe checkpoint inhibitor toxicity in more advanced disease ', ESMO OPEN, vol. 5, no. 6, 000945 . https://doi.org/10.1136/esmoopen-2020-000945
ESMO Open, 5(6). BMJ PUBLISHING GROUP
ESMO Open
Esmo Open, 5, 6
Esmo Open, 5
ESMO Open, 5(6):e000945. BMJ Publishing Group
ESMO Open, Vol 5, Iss 6 (2020)
ESMO Open, 5(6):000945. BMJ Publishing Group
ESMO Open, 5(6):000945. BMJ PUBLISHING GROUP
Verheijden, R J, May, A M, Blank, C U, van der Veldt, A A M, Boers-Sonderen, M J, Aarts, M J B, van den Berkmortel, F W P J, van den Eertwegh, A J M, de Groot, J W B, van der Hoeven, J J M, Hospers, G A P, Piersma, D, van Rijn, R S, ten Tije, A J, Vreugdenhil, G, van Zeijl, M C T, Wouters, M W J M, Haanen, J B A G, Kapiteijn, E & Suijkerbuijk, K P M 2020, ' Lower risk of severe checkpoint inhibitor toxicity in more advanced disease ', ESMO OPEN, vol. 5, no. 6, 000945 . https://doi.org/10.1136/esmoopen-2020-000945
ESMO Open, 5(6). BMJ PUBLISHING GROUP
ESMO Open
Contains fulltext : 229623.pdf (Publisher’s version ) (Open Access) BACKGROUND: Immune checkpoint inhibitor (ICI) can cause severe and sometimes fatal immune-related adverse events (irAEs). Since these irAEs mimick immunological disease, a female p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6b2810a24d327b462bf0cdb07832e35
https://research.vumc.nl/en/publications/7b0f1470-b2db-489e-b295-a031e5347867
https://research.vumc.nl/en/publications/7b0f1470-b2db-489e-b295-a031e5347867
Autor:
Edwin Cuppen, Stef van Lieshout, Hendrikus J. Dubbink, Paul Roepman, Marloes Steehouwer, Manon M. H. Huibers, Jacobus J.M. van der Hoeven, Kim Monkhorst, Lieke Schoenmaker, Willemina R. R. Geurts-Giele, Mariëtte E.G. Kranendonk, Bauke Ylstra, Mirjam C. Boelens, Floris H. Groenendijk, Alexander Hoischen, Wendy W.J. de Leng, Ewart de Bruijn, Margaretha G. M. Roemer, Kris G. Samsom
Publikováno v:
Roepman, P, de Bruijn, E, van Lieshout, S, Schoenmaker, L, Boelens, M C, Dubbink, H J, Geurts-Giele, W R R, Groenendijk, F H, Huibers, M M H, Kranendonk, M E G, Roemer, M G M, Samsom, K G, Steehouwer, M, de Leng, W W J, Hoischen, A, Ylstra, B, Monkhorst, K, van der Hoeven, J J M & Cuppen, E 2021, ' Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics ', Journal of Molecular Diagnostics, vol. 23, no. 7, pp. 816-833 . https://doi.org/10.1016/j.jmoldx.2021.04.011
Journal of Molecular Diagnostics, 23, 7, pp. 816-833
Journal of Molecular Diagnostics, 23, 816-833
Journal of Molecular Diagnostics, 23(7), 816-833. Association of Molecular Pathology
Journal of Molecular Diagnostics, 23, 7, pp. 816-833
Journal of Molecular Diagnostics, 23, 816-833
Journal of Molecular Diagnostics, 23(7), 816-833. Association of Molecular Pathology
Whole genome sequencing (WGS) using fresh frozen tissue and matched blood samples from cancer patients is becoming in reach as the most complete genetic tumor test. With a trend towards the availability of small biopsies and the need to screen an inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2e77afd0b0074d49a789ea249d925a6
https://doi.org/10.1101/2020.10.29.20222091
https://doi.org/10.1101/2020.10.29.20222091
Autor:
Franchette W P J van den Berkmortel, Jacobus J.M. van der Hoeven, M Schouwenburg, Albert J. ten Tije, Alfons J.M. van den Eertwegh, Michiel C T van Zeijl, Wim H. J. Kruit, John B. A. G. Haanen, Alexander C.J. van Akkooi, Rutger H. T. Koornstra, Maureen J.B. Aarts, Djura Piersma, Michel W.J.M. Wouters, Karijn P M Suijkerbuijk, A Jochems, Ellen Kapiteijn, Geke A. P. Hospers, Jan Willem B. de Groot, Gerard Vreugdenhil, Rozemarijn S. van Rijn
Publikováno v:
Cancers, 11(12):1940. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 11:WOS:000507382100117. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 11, 12
Schouwenburg, M G, Suijkerbuijk, K P M, Koornstra, R H T, Jochems, A, van Zeijl, M C T, van den Eertwegh, A J M, Haanen, J B A G, Aarts, M J, van Akkooi, A C J, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Kruit, W H, Piersma, D, van Rijn, R S, ten Tije, A J, Vreugdenhil, G, van der Hoeven, J J M & Wouters, M W J M 2019, ' Switching to immune checkpoint inhibitors upon response to targeted therapy; the road to long-term survival in advanced melanoma patients with highly elevated serum LDH? ', Cancers, vol. 11, no. 12, 1940 . https://doi.org/10.3390/cancers11121940
Cancers
Cancers, 11(12). Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 11
Cancers, 11(12):1940. MDPI AG
Cancers, 11:WOS:000507382100117. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 11, 12
Schouwenburg, M G, Suijkerbuijk, K P M, Koornstra, R H T, Jochems, A, van Zeijl, M C T, van den Eertwegh, A J M, Haanen, J B A G, Aarts, M J, van Akkooi, A C J, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Kruit, W H, Piersma, D, van Rijn, R S, ten Tije, A J, Vreugdenhil, G, van der Hoeven, J J M & Wouters, M W J M 2019, ' Switching to immune checkpoint inhibitors upon response to targeted therapy; the road to long-term survival in advanced melanoma patients with highly elevated serum LDH? ', Cancers, vol. 11, no. 12, 1940 . https://doi.org/10.3390/cancers11121940
Cancers
Cancers, 11(12). Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 11
Cancers, 11(12):1940. MDPI AG
Contains fulltext : 215533.pdf (Publisher’s version ) (Open Access) The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain
Autor:
Gerrit A. Meijer, Lizet E. van der Kolk, Lieke Schoenmaker, Kris G. Samsom, Jacobus J.M. van der Hoeven, Edwin Cuppen, Emile E. Voest, Luuk J. Schipper, Immy Riethorst, Ewart de Bruijn, Paul Roepman, Linda J.W. Bosch, Kim Monkhorst, Tineke E. Buffart
Publikováno v:
Journal of Clinical Oncology. 39:3013-3013
3013 Background: In the next few years numerous drugs will be approved for defined genomic targets, most of these in a tumor agnostic manner. Identifying patients who can benefit from this is critical for the future success of precision medicine, ide
Autor:
Djura Piersma, Margreet G. Franken, Geke A. P. Hospers, Jan Willem B. de Groot, Maureen J.B. Aarts, Rozemarijn S. van Rijn, B Leeneman, Marieke W. J. Louwman, Ellen Kapiteijn, Michel W.J.M. Wouters, Alfons J.M. van den Eertwegh, Willeke A. M. Blokx, Franchette W P J van den Berkmortel, Jacobus J.M. van der Hoeven, Hans Gelderblom, John B. A. G. Haanen, Albert J. ten Tije, Gerard Groenewegen, Gerard Vreugdenhil, M Schouwenburg, Mathilde C. Cardous-Ubbink, A Jochems, Carin A. Uyl-de Groot, Rutger H. T. Koornstra, Wim H. J. Kruit
Publikováno v:
European Journal of Cancer, 72, 156-165. ELSEVIER SCI LTD
Jochems, A, Schouwenburg, M G, Leeneman, B, Franken, M G, van den Eertwegh, A J M, Haanen, J B A G, Gelderblom, H, Uyl-de Groot, C A, Aarts, M J B, van den Berkmortel, F W P J, Blokx, W A M, Cardous-Ubbink, M C, Groenewegen, G, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Koornstra, R H, Kruit, W H, Louwman, M W, Piersma, D, van Rijn, R S, Ten Tije, A J, Vreugdenhil, G, Wouters, M W J M & van der Hoeven, J J M 2016, ' Dutch Melanoma Treatment Registry : Quality assurance in the care of patients with metastatic melanoma in the Netherlands ', European Journal of Cancer, vol. 72, pp. 156-165 . https://doi.org/10.1016/j.ejca.2016.11.021
European Journal of Cancer, 72, 156-165
European Journal of Cancer, 72, 156. Elsevier Limited
European Journal of Cancer, 72, 156-165. Elsevier Ltd.
European Journal of Cancer, 72, pp. 156-165
European Journal of Cancer, 72, 156-165. Pergamon
Jochems, A, Schouwenburg, M G, Leeneman, B, Franken, M G, van den Eertwegh, A J M, Haanen, J B A G, Gelderblom, H, Uyl-de Groot, C A, Aarts, M J B, van den Berkmortel, F W P J, Blokx, W A M, Cardous-Ubbink, M C, Groenewegen, G, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Koornstra, R H, Kruit, W H, Louwman, M W, Piersma, D, van Rijn, R S, Ten Tije, A J, Vreugdenhil, G, Wouters, M W J M & van der Hoeven, J J M 2016, ' Dutch Melanoma Treatment Registry : Quality assurance in the care of patients with metastatic melanoma in the Netherlands ', European Journal of Cancer, vol. 72, pp. 156-165 . https://doi.org/10.1016/j.ejca.2016.11.021
European Journal of Cancer, 72, 156-165
European Journal of Cancer, 72, 156. Elsevier Limited
European Journal of Cancer, 72, 156-165. Elsevier Ltd.
European Journal of Cancer, 72, pp. 156-165
European Journal of Cancer, 72, 156-165. Pergamon
Contains fulltext : 174807.pdf (Publisher’s version ) (Closed access) BACKGROUND: In recent years, the treatment of metastatic melanoma has changed dramatically due to the development of immune checkpoint and mitogen-activated protein (MAP) kinase
Autor:
Djura Piersma, Alfons J.M. van den Eertwegh, Alexander C.J. van Akkooi, Franchette W P J van den Berkmortel, Jacobus J.M. van der Hoeven, John B. A. G. Haanen, Gerard Vreugdenhil, M Schouwenburg, Ellen Kapiteijn, Michel W.J.M. Wouters, Geke A. P. Hospers, Karijn P M Suijkerbuijk, Jan Willem B. de Groot, Willeke A. M. Blokx, Rozemarijn S. van Rijn, Albert J. ten Tije, A Jochems, B Leeneman, Maureen J.B. Aarts, Wim H. J. Kruit, Rutger H. T. Koornstra, Michiel C T van Zeijl, Margreet G. Franken, Marieke W. J. Louwman
Publikováno v:
Melanoma Research, 28, 326-332
Melanoma Research, 28, 4, pp. 326-332
Melanoma Research, 28(4), 326-332. Lippincott Williams & Wilkins
Melanoma Research, 28(4), 326-332. LIPPINCOTT WILLIAMS & WILKINS
Melanoma Research, 28(4), 326. Lippincott Williams and Wilkins
Schouwenburg, M G, Jochems, A, Leeneman, B, Franken, M G, van den Eertwegh, A J M, Haanen, J B A G, van Zeijl, M C T, Aarts, M J, van Akkooi, A C J, van den Berkmortel, F W P J, Blokx, W A M, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Koornstra, R H, Kruit, W H, Louwman, M W J, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, Vreugdenhil, G, Wouters, M W J M & van der Hoeven, J J M 2018, ' Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: Prognostic factors associated with clinical outcomes ', Melanoma Research, vol. 28, no. 4, pp. 326-332 . https://doi.org/10.1097/CMR.0000000000000453
Melanoma Research, 28(4), 326-332. Lippincott Williams and Wilkins
Melanoma Research, 28(4), 326-332
Melanoma Research, 28, 4, pp. 326-332
Melanoma Research, 28(4), 326-332. Lippincott Williams & Wilkins
Melanoma Research, 28(4), 326-332. LIPPINCOTT WILLIAMS & WILKINS
Melanoma Research, 28(4), 326. Lippincott Williams and Wilkins
Schouwenburg, M G, Jochems, A, Leeneman, B, Franken, M G, van den Eertwegh, A J M, Haanen, J B A G, van Zeijl, M C T, Aarts, M J, van Akkooi, A C J, van den Berkmortel, F W P J, Blokx, W A M, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Koornstra, R H, Kruit, W H, Louwman, M W J, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, Vreugdenhil, G, Wouters, M W J M & van der Hoeven, J J M 2018, ' Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: Prognostic factors associated with clinical outcomes ', Melanoma Research, vol. 28, no. 4, pp. 326-332 . https://doi.org/10.1097/CMR.0000000000000453
Melanoma Research, 28(4), 326-332. Lippincott Williams and Wilkins
Melanoma Research, 28(4), 326-332
The aim of this population-based study was to identify the factors associated with clinical outcomes in vemurafenib-treated patients and to evaluate outcomes across subgroups of patients with different risk profiles. Data were retrieved from the Dutc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2624cc827142bef034456a349c84a18
https://hdl.handle.net/1887/96180
https://hdl.handle.net/1887/96180
Autor:
Judith R. Kroep, An K.L. Reyners, Jacobus J.M. van der Hoeven, Arien R. van Erkel, Toos Daemen, Cornelis J. M. Melief, Sjoerd H. van der Burg, Marij J. P. Welters, Mariëtte I.E. van Poelgeest, Hans W. Nijman, Renske Goedemans, Vincent T.H.B.M. Smit, Saskia J. A. M. Santegoets, Eveline M. Dijkgraaf
Publikováno v:
Oncotarget
Oncotarget, 6, 31, pp. 32228-43
Oncotarget, 6(31), 32228-32243
Oncotarget, 6, 32228-43
Oncotarget, 6(31), 32228-32243. Impact Journals LLC
Oncotarget, 6, 31, pp. 32228-43
Oncotarget, 6(31), 32228-32243
Oncotarget, 6, 32228-43
Oncotarget, 6(31), 32228-32243. Impact Journals LLC
// Eveline M. Dijkgraaf 1 , Saskia J.A.M. Santegoets 1 , An K.L. Reyners 2 , Renske Goedemans 1 , Hans W. Nijman 3 , Mariette I.E. van Poelgeest 4 , Arien R. van Erkel 5 , Vincent T.H.B.M. Smit 6 , Toos A.H.H. Daemen 7 , Jacobus J.M. van der Hoeven 1